Inflammatory faCtors AfteR acUte Ischemic Stroke

Summary

ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke. The aims of the study are to i) define the characteristics and determinants of microglial activation after human stroke, and ii) assess the correlation of microglial activation with circulating inflammatory markers, structural brain changes on neuroimaging, and neurological outcomes.

ICARUS involves serial TSPO-PET imaging along with serial MRI, immune cell profiling in blood, and both clinical and laboratory assessments in 36 patients with acute ischemic stroke caused by a cortical (N=18) or strictly subcortical (N=18) infarct.

In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer.

Conditions

• Ischemic Stroke

Interventions

DIAGNOSTIC_TEST

[18F]-GE-180 PET

serial \[18F\]-GE-180 PET imaging to assess microglia activation

DIAGNOSTIC_TEST

3T MRI

serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness

DIAGNOSTIC_TEST

immune cell profiling in blood

Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.

Sponsors & Collaborators

• Universitätsklinikum Hamburg-Eppendorf

  collaborator OTHER

• University Hospital Muenster

  collaborator OTHER

• Martin Dichgans

  lead OTHER

Principal Investigators

• Martin Dichgans, Prof. · LMU Munich

• Peter Bartenstein, Prof. · LMU Munich

• Sibylle Ziegler, Prof. · LMU Munich

Study Design

Allocation

NA

Purpose

BASIC_SCIENCE

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-01

Primary Completion

2026-12-31

Completion

2027-12-31

Countries

• Germany

Study Locations